Moderna (MRNA) Tops Q2 EPS by 85c; offers guidance

Moderna (NASDAQ: MRNA) reported Q2 EPS of ($2.13), $0.85 better than the analyst estimate of ($2.98). Revenue for the quarter came in at $142 million versus the consensus estimate of $114.4 million.

GUIDANCE:

Moderna sees FY2025 revenue of $1.5-2.2 billion, versus the consensus of $2.068 billion.

For earnings history and earnings-related data on Moderna (MRNA) click here.

You May Also Be Interested In

• Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
• Quantum Cyber submits confidential white paper to U.S. Army program
• Robinhood Markets (HOOD) PT Raised to $130 at Compass Point